FDA recall, , Moderate risk
Avet Pharmaceuticals Clindamycin Palmitate Hydrochloride for Oral Solution
Clindamycin palmitate hydrochloride oral solution contains particles and white flakes in reconstituted bottles.
Summary by Recall Canary from the FDA notice
What happened
Heritage Pharmaceuticals Inc. of East Brunswick, New Jersey, recalled Clindamycin Palmitate Hydrochloride for Oral Solution, USP, 75 mg/5 mL, Rx Only, 100 mL, distributed by Avet Pharmaceuticals Inc., because the reconstituted bottles contain particles and white flakes. The recall began July 30, 2026, and was added to the FDA's Enforcement Report on August 10, 2026. The product was distributed nationwide within the U.S.
What to do
We don't have product-specific instructions for this recall. FDA's general advice for medicine recalls:
- Check the FDA or company notice for instructions specific to this product.
- Ask your pharmacist or doctor whether your lot is affected and what to do.
Is yours affected?
Match the NDC and lot code listed under your product.
An NDC (National Drug Code) is usually printed on the drug's label.
Clindamycin Palmitate Hydrochloride for Oral Solution, USP, 75 mg/5 ml
- NDC
- 23155-603-51
- Lot code
- 2411550
Recall details
- Company began the recall
- Sold in
Nationwide within the U.S
- Company
- Heritage Pharmaceuticals IncEast Brunswick, New Jersey
- Hazard
- Foreign object
- Risk
Moderate risk
Taking it may cause short-term health problems, or ones that treatment can reverse. Serious harm is unlikely.
FDA Class II recall · How risk is rated
- Event ID
- 99526
- Recall number
- D-0768-2026
Timeline
FDA's Enforcement Report is its public list of recalls; FDA adds a recall when it posts it and publishes the list weekly.
Company began the recall
Added to FDA's Enforcement Report
Listed on Recall Canary
Classified by FDA
In FDA's weekly enforcement report
Summary updated
